Mechanisms of bortezomib in the treatment of pulmonary hypertension

doi:10.12092/j.issn.1009-2501.2019.08.018

Abstract

Abstract:

Bortezomib (BTZ) can inhibit the proliferation of many kinds of cell. Studies have shown promising evidence of BTZ in the treatment of multiple myeloma and tumor. To date, researchers have believed the proliferation and migration of pulmonary artery smooth muscle cells (PASMC) play as the two major causes that induce the excessive thickening and remodeling of the distal pulmonary arteries (PA), which drives the disease pathogenesis of pulmonary hypertension (PH). Lately, a number of recent studies have indicated that BTZ can effectively suppress the PH development in multiple commonly used PH rat models via inhibiting the distal PA remodeling and PASMC proliferation. However, neither the underlying molecular mechanism nor the related clinical relevance are fully understood and remain future dissection. Therefore, in this review, we briefly summarize the recent published literature, which provide mechanistic evidence to guide the utilization of BTZ as a potential novel treatment option in PH and other pulmonary vascular diseases.

Key words: bortezomib, pulmonary hypertension

CLC Number:

R543.2

WANG Chao, GeGentuya, XU Lei. Mechanisms of bortezomib in the treatment of pulmonary hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 957-960.

References

［1］de Jesus Perez VA. Molecular pathogenesis and current pathology of pulmonary hypertension［J］. Heart Fail Rev, 2016,21(3):239-257.
［2］魏子寒,李栋博,元峥,等.沙库巴曲缬沙坦治疗左心疾病相关性肺动脉高压的临床研究［J］.中国临床药理学与治疗学,2019,24(1):57-62.
［3］Oka M, Homma N, Taraseviciene-Stewart L, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats［J］. Circ Res, 2007,100(6):923-929.
［4］Wade BE, Zhao J, Ma J, et al. Hypoxia-induced alterations in the lung ubiquitin proteasome system during pulmonary hypertension pathogenesis［J］. Pulm Circ, 2018, 8(3):1-13
［5］Kaufman JL, Nooka A, Vrana M, et al. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study［J］.Cancer, 2010,116(13):3143-3151.
［6］Hussein MA. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma［J］. Oncologist, 2002, 7 (Suppl 1): 20-29.
［7］Ri M. Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma［J］. Rinsho Ketsueki, 2018, 59(10): 2162-2168.
［8］Rogers N, Paine S, Bedford L, et al. Review: the ubiquitin-proteasome system: contributions to cell death or survival in neurodegeneration［J］. Neuropathol Appl Neurobiol, 2010,36(2):113-124.
［9］Moore BS, Eustáquio AS, McGlinchey RP. Advances in and applications of proteasome inhibitors［J］. Curr Opin Chem Biol, 2008,12(4):434-440.
［10］Harrison BC, Bell ML, Allen DL, et al. Skeletal muscle adaptations in response to voluntary wheel running in myosin heavy chain null mice［J］. J Appl Physiol，2002,92(1):313-322.
［11］Kim SY, Lee JH, Huh JW, et al. Bortezomib alleviates experimental pulmonary arterial hypertension［J］. Am J Respir Cell Mol Biol, 2012,47(5):698-708.
［12］Wang Z, Yang K, Zheng Q, et al. Divergent Changes of p53 in pulmonary arterial endothelial and smooth muscle cells involved in the development of pulmonary hypertension［J］. Am J Physiol Lung Cell Mol Physiol, 2018, 316(1):L216-L228.
［13］Xie X, Wang G, Zhang D, et al. Activation of peroxisome proliferator-activated receptor γ ameliorates monocrotaline-induced pulmonary arterial hypertension in rats［J］.Biomed Rep,2015,3(4):537-542.
［14］Wang Y, Lu W, Yang K, et al. Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entry［J］.J Mol Med (Berl),2015,93(3):327-342.
［15］Lee YR, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects［J］. Nat Rev Mol Cell Biol, 2018,19(9):547-562.
［16］Kuhr FK, Smith KA, Song MY, et al. New mechanisms of pulmonary arterial hypertension: role of Ca2+ signaling［J］. Am J Physiol Heart Circ Physiol, 2012, 302(8): H1546-1562.
［17］Wang J, Weigand L, Lu W, et al. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells［J］. Circ Res, 2006,98(12):1528-1537.
［18］徐磊, 田国英, 王立红, 等. 硼替佐米对低氧诱导的肺动脉平滑肌细胞Orai-1蛋白表达的影响［J］.中华结核和呼吸杂志,2017,(2):118-122.
［19］Ibrahim YF, Wong CM, Pavlickova L, et al. Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing［J］. J Am Heart Assoc, 2014,3(1):e000520.
［20］Wong CM, Cheema AK, Zhang L, et al. Protein carbonylation as a novel mechanism in redox signaling［J］. Circ Res, 2008,102(3):310-318.
［21］Lee SJ, Smith A, Guo L, et al. Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension［J］. Am J Respir Crit Care Med, 2011,183(5):649-658.
［22］Jiang J, Cyr D, Babbitt RW, et al. Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the co-chaperone/ubiquitin ligase CHIP［J］. J Biol Chem, 2003,278(49):49332-49341.
［23］Michel T, Vanhoutte PM. Cellular signaling and NO production［J］. Pflugers Arch, 2010,459(6):807-816.
［24］Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells［J］. Metabolism, 2001,50(1):3-11.
［25］Kaplan GS, Torcun CC, Grune T, et al. Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect［J］. Free Radic Biol Med, 2017,103:1-13.
［26］Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy［J］. Toxicol, 2012,291(1-3):1-9.
［27］Karademir B, Sari G, Jannuzzi AT, et al. Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib［J］. Sci Rep, 2018,8(1):16318.
［28］Wang X, Ibrahim YF, Das D, et al. Carfilzomib reverses pulmonary arterial hypertension［J］. Cardiovasc Res, 2016,110(2):188-199.

[1]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[2]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[3]	WANG Rui, PAN Jinjin, LI Hua, YUAN Yuhui. Research progress of melatonin on pulmonary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 444-448.
[4]	HU Xiaoyan, XU Qiuping. Application of levosimendan in severe patients after cardiac surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1027-1032.
[5]	XU Jing, JIN Xiaojie. Effect of fasudil combined with sildenafil in the treatment of pulmonary hypertension in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 281-286.
[6]	HUANG You-ming, WANG An-cai, ZHA Ri-tian. Observation on combined seretide with theophylline on the pulmonary artery pressure and right cardiac functionin in patients with stable chronic obstructive pulmonary disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 920-925.
[7]	CHEN Hui, QU Li, HUANG Yong-gang. Cytotoxic activity of bortezomib against gastric cancer and its action mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 606-609.
[8]	WU Cai-xia, DU Guan-hua. Pulmonary vascular endothelial injury and pulmonary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 463-471.
[9]	WU Jun, WANG Liang-xing, YING Bing-yu, SHI Meng-ru. Change of calreticulin precursor in pulmonary hypertension rats interfered with puerarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 14-19.
[10]	ZHOU Yong-lie, LV Ya-ping, XU Wu-lin, HU Wei-xiao. Determination of proteasome activities with fluorescence kinetic assay and its application in screening proteasome inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1127-1133.
[11]	MO Bi-wen, ZENG Jin-rong, LI Guo-jian, HUANG Wen-xin, YU Fang, WANG Ji-ying, WANG Chang-ming. Effects of chloride channel blocker on hypoxia induced rat pulmonary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 677-680.
[12]	. Affinity and selectivity of darusentan for rat endothelin receptors and effects of once iv administration of darusentan on hypoxia-induced pulmonary hypertensive in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(3): 261-265.
[13]	WANG Hong, XIE Wei-ping, WANG Hai, HU Gang. Effects of iptakalim on endothelin-1-induced pulmonary hypertension in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(1): 9-14.
[14]	CHEN Yan-fan, CHEN Shao-Xian, FAN Xiao-Fang, WANG Liang-Xing. Expression of vascular endothelial growth factor in chronic hypoxia and hypercapnia rats and effects of SHENYI Capsule [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(6): 709-712.
[15]	YANG Peng-Lin, YU Lin-Sheng, GONG Yong-Sheng, ZHENG Lu-Zhen, WANG Wei, HU Liang-Gang. Influences of perindopril on pulmonary vascular remodeling in normobaric hypoxia-hypercapnia rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(4): 305-308.